Clinical Trial Update: PARPi and Ovarian Cancer Survival

View source ↗

Summary

A not-yet-recruiting clinical trial is investigating a PARP inhibitor for epithelial ovarian cancer and related cancers of the fallopian tube or peritoneum.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer

Drugs mentioned

• PARP inhibitor

Snippet

Sponsor: Shanghai Gynecologic Oncology Group | Conditions: Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum, PARP Inhibitor | Status: NOT_YET_RECRUITING